Author Archives: admin

– Financing will support development of a foundational machine learning model of medicinal chemistry that can accurately predict small molecule drug candidates for any protein – – Releases unprecedented dataset publicly to address critical challenges in drug discovery with machine learning – SALT LAKE CITY, April 05, 2024 (GLOBE NEWSWIRE) — Leash Biosciences, an artificial […]

SALT LAKE CITY, UT, March 19, 2024 (Business Wire) – Seek Labs, a healthcare innovations company developing next-generation molecular diagnostic systems and novel CRISPR-based gene therapies, is pleased to announce the appointment of Michael Paul, PhD to its Board of Directors, effective March 18, 2024. With decades of experience in life sciences innovation, capital formation, […]

SALT LAKE CITY, March 21, 2024 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and Trademark Office has issued a patent that will strengthen its ability to deliver a tumor-informed, high-definition, molecular residual disease (MRD) assay to market. U.S. patent […]

HEBER CITY, Utah, Feb. 13, 2024 /PRNewswire/ — Wasatch Biolabs (WBL), a subsidiary of Renew Biotechnologies and a certified Oxford Nanopore Technologies’ laboratory, launches a proprietary Targeted DNA Methylation Sequencing Service for researchers and clinical service providers. The technique is amplification and bisulfite conversion free, effectively bypassing the most common limitations of targeted methylation analysis […]

Presentation included announcement of the opening of the new manufacturing facility in Salt Lake City, UT SALT LAKE CITY, March 21, 2024 /PRNewswire/ — Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that in his keynote address […]

VALENCIA, Calif. – March 20, 2024 – Nusano, a physics company transforming the production of medical radioisotopes, will present at the 7th Theranostics World Congress taking place March 22-24, 2024, in Santiago, Chile. Greg Moffitt, Nusano Director of Target Development, will provide an overview of the company’s proprietary radioisotope production platform on Sunday, March 24. […]

Micro ACE combines a unique balance of stiffness and resiliency to achieve successful micro-access in challenging cases SOUTH JORDAN, Utah, March 19, 2024 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced commercial release of its US Food and Drug Administration (FDA)-cleared Micro ACE Advanced Micro-Access System. […]

Successful Completion of Upsized $12M Placing NEW YORK and SALT LAKE CITY, March 12, 2024 – Renalytix plc (NASDAQ: RNLX) (LSE: RENX) is pleased to announce that following its announcement earlier today regarding a proposed Placing of Ordinary Shares (the “Launch Announcement“), it has successfully placed 46,801,872 Ordinary Shares (the “Placing Shares“) with both UK and US institutional […]

 It was another banner year for the Wilson Sonsini Entrepreneur & Investor Life Sciences Summit (E&I Summit), presented by BioUtah and the University of Utah Technology Licensing Office. The 2024 E&I Summit included activities from March 13-15 with the main Summit event held, March 14 at the Sheraton in Salt Lake City. Over 450 registrants […]

Cellvizio Food Intolerance Test (C-FIT) delivers real-time, in vivo visibility to accurately identify food intolerance in patients suffering from Irritable Bowel Syndrome (IBS) Metrodora will serve as Center of Excellence for patient care and physician training to enable broad access to this breakthrough procedure Paris, Boston and Salt Lake City, March 6, 2024 – 5:45 […]

BOSTON, March 4, 2024 /PRNewswire/ — Constant Therapeutics LLC, a biopharmaceutical company focused on the development of treatments impacting the Alternative Renin-Angiotensin System, today announced that the first patient was dosed March 3, 2024, in the Company’s phase 2 clinical trial of TXA127, the Company’s lead peptide product under development as a potential treatment for […]

Offer Now Scheduled to Expire at 5:00 p.m., New York Time, on April 30, 2024 WALTHAM, Mass.–(BUSINESS WIRE)– Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, announced that its wholly owned subsidiary, Orion Acquisition AB (the “Buyer”), has extended the expiration time of the offering period of its previously […]